Dr Dejan Brkic
Dr Dejan Brkic is Senior Director Regulatory Strategy, Thermo Fisher Scientific
EditorialClinical trial design and real-world evidence: What happens to the evidence next?
When does a clinical trial really end? This October issue of Regulatory Rapporteur explores the evidence continuum from clinical trial design to real-world use, examining diversity, decentralised trials, AI-enabled pharmacovigilance, regulatory convergence, disclosure and the global implementation of Good Clinical Practice. Together, these contributions consider how data are generated, managed and interpreted across the product lifecycle and what this means for evidence-based decision-making.
EditorialAccess to medicines: From approval to
patient-centred deliveryThis issue focuses on access to medicines, and demonstrates how lifecycle regulation, diverse evidence, operational innovation and corss-sector collaboration all contribute to improving the timely, equitable and trusted delivery of medicines.
JournalRegulatory affairs as a strategic function in market access of medicinal products: Pre‑COVID-19 context, COVID-19 acceleration and post‑COVID-19 convergence across 11 markets
This article looks at how regulator, HTA body and payer interfaces have evolved since the COVID-19 pandemic and how regulatory affairs has become a strategic integrator of regulation, evidence and access




















